Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

American Heart Association honors Mount Sinai’s Valentin Fuster, MD, PhD, for his global leadership

The American Heart Association (AHA) has awarded world-renowned cardiologist Dr. Valentin Fuster, MD, PhD, Director of Mount Sinai Heart at The Mount Sinai Medical Center, its prominent American Heart Association/American Stroke Association Ron Haddock International Impact Award.

July 1, 2013

Academy of Nutrition and Dietetics collaborates on bipartisan Medicare bill to treat and reduce obesity

A promising bipartisan bill that increases vital access and reimbursement for obesity screening and counseling services has been introduced in Congress, thanks in part to the Academy of Nutrition and Dietetics.

June 20, 2013

Bioengineered vein: A first in U.S.

Vascular surgeon Jeffrey H. Lawson, MD, PhD, implanted a bioengineered vein graft June 5 in a patient with end-stage kidney disease in a two-hour procedure at Duke University Hospital in Durham. The operation launches the U.S. trial of the human cell-based product that Lawson helped develop. If the bioengineered veins prove beneficial for hemodialysis patients, then they may try to develop a graft for heart bypass surgeries.

June 7, 2013

Avandia: The sequel

The New York Times set the stage for the upcoming FDA meeting that revisits GlaxoSmithKline’s diabetes drug, rosiglitazone (Avandia). The FDA said it is trying to “resolve uncertainty” about the drug, which has been limited based on concerns about heightened cardiovascular risk.   

June 3, 2013

Up in arms over ARBs

According to a report in the Wall Street Journal, FDA officials are in a tussle over angiotensin-receptor blockers (ARBs). Based on evidence of an increased risk in cancer, one reviewer argues for a stronger warning but his bosses aren’t convinced. They describe such action as a diversion from assessing new drug applications.

May 31, 2013

Grant funds cardiac stem cell research for Duchenne muscular dystrophy-related heart disease

Newport Beach-based nonprofit Coalition Duchenne has awarded a $150,000 grant to a Cedars-Sinai Heart Institute team investigating whether an experimental cardiac stem cell treatment could be used to treat Duchenne muscular dystrophy patients who have developed heart disease.

May 31, 2013

POZEN announces FDA acceptance of filing of New Drug Application for PA32540/PA8140 tablets

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review, the New Drug Application (NDA) for PA32540/PA8140.

May 29, 2013

Physician innovator of heart valve repair receives Cedars-Sinai Heart Institute’s Corday Prize in Heart Research

Cedars-Sinai Heart Institute is honoring the physician widely known as  the leading pioneer in modern mitral heart valve repair, Alain Carpentier, MD, PhD, with the second annual Eliot Corday, MD, International Prize in Heart Research. The Cedars-Sinai Heart Institute established the Corday Prize to recognize physicians and scientists conducting groundbreaking research, or individuals who significantly advance the practice of heart medicine.

May 22, 2013

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup